Utilizing hiPSC-Derived Neurons and Cardiomyocytes For Drug Screening

Tuesday, 5 April 2016 at 11:45

Add to Calendar ▼2016-04-05 11:45:002016-04-05 12:45:00Europe/LondonUtilizing hiPSC-Derived Neurons and Cardiomyocytes For Drug ScreeningStem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

Patient-specific primary cells and human induced pluripotent stem cells (hiPSC) complement traditional cell-based drug discovery assays and could aid in the development of clinically useful compounds. We will discuss our high content screening results and development of patient specific hiPSC based models for drug discovery.

Anne Bang, Director, Sanford Burnham Medical Research Institute

Anne Bang

Anne Bang joined the Sanford|Burnham|Prebys Medical Discovery Institute in June 2010 as Director of Cell Biology at the Conrad Prebys Center for Chemical Genomics, a state of the art drug discovery center. Dr. Bang’s research focus is to develop iPSC-based disease models for drug discovery. Prior to joining SBP she was at ViaCyte Inc. as Director of Stem Cell Research, where she managed an interdisciplinary group of scientists working to develop hESC as a replenishable source of pancreatic cells for the treatment of diabetes. Dr. Bang has over 20 years of experience in the field of developmental biology, with a focus on neural development. She received her BS from Stanford University, her Ph.D. in Biology from UCSD, and was a post-doctoral fellow at the Salk Institute.